ChemAbout
© 2026 ChemAbout
İçgörüler|Gizlilik Politikası|Kullanım Koşulları|[email protected]
Ana Sayfa/Bileşikler/Aktif Farmasötik İngredient/{4-[(2S)-2-[(2S)-2-(1-amino-3,6,9,12-tetraoxapentadecan-15-amido)-3-methylbutanamido]-5-(carbamoylamino)pentanamido]phenyl}methyl N-[(1S)-1-{[(1S)-1-{[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-2-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]carbamoyl}-1-methoxy-2-methyleth
C69H115N11O17
1370.7 g/mol
Aktif Farmasötik İngredient

{4-[(2S)-2-[(2S)-2-(1-amino-3,6,9,12-tetraoxapentadecan-15-amido)-3-methylbutanamido]-5-(carbamoylamino)pentanamido]phenyl}methyl N-[(1S)-1-{[(1S)-1-{[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-2-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]carbamoyl}-1-methoxy-2-methyleth

CAS1492056-71-9
Kategori
Aktif Farmasötik İngredient
Bileşik Sınıfı
Peptit
Birincil Kullanım
Farmasötik ham madde

This compound is a synthetic antibody-drug conjugate payload consisting of the antimitotic agent monomethyl auristatin E linked to a cleavable peptide spacer and a PEGylated solubilizing group. It is primarily used as a pharmaceutical raw material in the manufacturing of antibody-drug conjugates for targeted cancer research.

antibody-drug conjugate manufacturingtargeted cancer research

İçerik kapsamı: Bu sayfadaki bilgiler kimyasal tanımlama ile endüstriyel tedarik, araştırma ve üretim bağlamlarına ilişkindir. Tedavi iddiası, tıbbi tavsiye veya ilaç kullanım talimatı niteliği taşımaz.

Bu bileşiği tedarik ediyor veya sağlıyor musunuz?

Envanterinizi listeleyin veya satın alma talebi gönderin

CAS 1492056-71-9

Bu Ürünü Listele
Tedarik bilgisi yayınlamak için oturum açın
Bu Ürünü Talep Et
Kayıt olmadan talep gönderin

İlgili Bileşikler

GüçlüBenzer yapıBenzerlik 0.90

[4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[3-[2-[2-[2-[2-[2-[2-[2-[2-(2,5-dioxopyrrol-1-yl)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate

CAS2353409-69-3

Antibody drug conjugate payload

GüçlüBenzer yapıBenzerlik 0.88

MAL-di-EG-Val-Cit-PAB-MMAE

CAS2746391-62-6

antibody-drug conjugate linker payload

GüçlüBenzer yapıBenzerlik 0.86

Acetylene-linker-Val-Cit-PABC-MMAE

CAS1411977-95-1

antibody-drug conjugate linker payload

GüçlüBenzer yapıBenzerlik 0.85

[4-[[(2S)-2-[[(2S)-2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate

CAS2684216-48-4

Antibody-drug conjugate payload

UygulamaAynı kullanım

MC-Val-Cit-PAB-MMAF

CAS863971-17-9

antibody-drug conjugate payload

UygulamaAynı kullanım

Tesirine

CAS1595275-62-9

antibody-drug conjugate payload

UygulamaAynı kullanım

Mc-ggfg-dxd(1)

CAS1599440-13-7

antibody-drug conjugate payload

UygulamaAynı kullanım

(2S)-N-[(2S)-1-[4-[(6aS)-3-[3-[[(6aS)-2-methoxy-8-(4-methoxyphenyl)-11-oxo-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]propoxy]-2-methoxy-11-oxo-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-8-yl]anilino]-1-oxopropan-2-yl]-2-amino-3-methylbutanamide

CAS2057431-94-2

antibody-drug conjugate payload

Tanımlayıcılar
IUPAC Adı

[4-[[(2S)-2-[[(2S)-2-[3-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]propanoylamino]-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate

InChIKey

QTTIHRGTMDWEEX-SFLKBQQHSA-N

SMILES

CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@H](C)[C@H](C2=CC=CC=C2)O)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(C)C(=O)OCC3=CC=C(C=C3)NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)CCOCCOCCOCCOCCN

Eş Anlamlılar (1)

—